This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Berndt, M. C. Articles by Andrews, R. K. Search for Related Content PubMed PubMed Citation Articles by Berndt, M. C. Articles by Andrews, R. K. Pubmed/NCBI databases Substance via MeSH Related Collections Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:205.)
© 2008 American Heart Association, Inc.

Editorials

New Direction for WE Thrombin

Michael C. Berndt; Robert K. Andrews

From the Department of Immunology, Alfred Medical Research and Education Precinct (AMREP), Melbourne, Victoria, Australia.

Correspondence to Professor Michael C. Berndt, Department of Immunology, Monash University, Alfred Medical Research and Education Precinct (AMREP), Commercial Road, Melbourne, Victoria, Australia 3004. E-mail michael.berndt@med.monash.edu.au

Key Words: platelets • thrombin • thrombus formation • GPIb-IX-V

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
An appealing strategy for developing therapeutic agents is to modify the design of human proteins, thereby taking advantage of target-specificity, multifunctionality of many proteins, and human compatibility—that is, provided any undesirable functional effects of the parent molecule can be selectively engineered away. In 2000, Cantwell & Di Cera¹ reported a mutant form of the human serine protease, -thrombin, a multifunctional enzyme involved in both pro- and antithrombotic pathways. This mutant, termed WE thrombin, containing Trp215Ala and Glu217Ala substitutions, still promoted formation of activated protein C (APC) that inhibits coagulation factors Va and VIIIa (antithrombotic), but inefficiently converted fibrinogen to fibrin (prothrombotic), and was an effective antithrombotic agent in primate models of thrombosis.^2,3 But a number of observations suggested this was not the full story. For instance, at low WE thrombin concentrations, there was a greater antithrombotic effect than expected based on circulating APC levels and minimal systemic anticoagulation, and in addition, labeled WE thrombin was incorporated into a developing thrombus, suggesting it might be interacting with platelets. In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Berny and colleagues⁴ have provided further information (see Figure), revealing an unanticipated additional antithrombotic effect of WE thrombin, that is, binding to platelet glycoprotein (GP)Ib (the major ligand-binding subunit of the GPIb-IX-V complex),^5–7 and inhibiting platelet adhesion to von Willebrand factor (vWF) under hydrodynamic flow and thrombus formation on a collagen matrix. The interaction of both wild-type and WE thrombin with GPIb involves the N-terminal ligand-binding region of GPIb (residues 1 to . . . [Full Text of this Article]

Related Article:

Thrombin Mutant W215A/E217A Acts as a Platelet GPIb Antagonist

Michelle A. Berny, Tara C. White, Erik I. Tucker, Leslie A. Bush-Pelc, Enrico Di Cera, András Gruber, and Owen J.T. McCarty
Arterioscler Thromb Vasc Biol 2008 28: 329-334. [Abstract] [Full Text] [PDF]